A Phase 3b Clinical Study to Assess Whether Regular Administration of ADVATE in the Absence of Immunological Danger Signals Reduces the Incidence Rate of Inhibitors in Previously Untreated Patients with Hemophilia A. Early Prophylaxis Immunologic Challen

Grants and Contracts Details

StatusFinished
Effective start/end date6/19/126/30/14

Funding

  • Baxter Healthcare Co: $6,615.00